The combined market share of the largest Russian pharmaceutical distributors within the TOP-25 in the direct deliveries segment amounted to 77% as of the first three quarters of 2025. Over the year, the level of concentration in the wholesale segment increased only marginally — by just 0.55%.

Ranking of Pharmacy Chains and Associations by Share of the Commercial Retail Market for Medicines in Russia, January–September 2025

From January through October 2025, pharmaceutical companies localized in the Russian Federation released into circulation more than 3.26 billion packs of finished medicinal products (FMPs), equivalent to 68.89 billion minimum dosage units (MDUs).

In Q1–Q3 2025 the Russian retail market featured sales of nearly 6,000 pharmaceutical brands represented by 803 corporations. Over the first nine months of the year, the market volume for medicinal products reached RUB 1.36 trillion (in retail prices, including VAT), with value growth of 15.7% year-on-year compared to the same period in 2024.

In 2025, the total volume of the Russian pharmaceutical market is highly likely to surpass another psychological milestone of RUB 3 trillion (in end-consumer prices, including VAT); the value dynamics relative to 2024 are expected to reach 16%.

The total volume of finished medicine production in our country in Q1-Q2 2025 amounted to 475.9 billion rubles (at manufacturer shipment prices, including VAT). The growth rate compared to the same period in 2024, when calculated in Russian currency, reached 20.2%.

Retail sales of alcohol dependence treatment medicines exceeded 539.6 million rubles in the first half of 2025 at retail prices, including VAT.

Over the past few years, Russia has seen steady growth in sales of hormonal contraceptives (EphMRA classification group G03A). The exception was 2023, when sales of such products declined by 1% compared to 2022, due to frenzied demand during the comparison period.